Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Osteoporosis 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Cystic Fibrosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Diseases 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 21Radiotherapy 9Chemotherapy, Adjuvant 9Specimen Handling 8Early Intervention, Educational 8Anastrozole 7Neoadjuvant Therapy 6Methods 6Letrozole 6Psychiatric Rehabilitation 5Practice Guidelines as Topic 5Immunohistochemistry 5Counseling 5Biopsy 5Standard of Care 4Mastectomy, Segmental 4Mass Spectrometry 4Magnetic Resonance Spectroscopy 4Gene Expression Profiling 4Educational Status 4Behavior Therapy 4exemestane 3Radiation Dose Hypofractionation 3Radiation 3Brachytherapy 3Watchful Waiting 2Therapeutics 2Telemedicine 2Taxes 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Carcinoma In Situ × Bone Density × Clear all
NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Mayo Clinic

Phase 2 Recruiting
38 enrolled
Breast

Breast Carcinoma In Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡